LR3-IGF-I (Receptor Grade), Human
| $53.00 | |
| Z03177-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $53.00 | |
| Z03177-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | |
| Protein Construction |
Expressed with additional N-terminal sequence (MFPAMPLSSLFVNGPRT).
|
|
| Purity | > 95% as analyzed by SDS-PAGE | |
| Endotoxin Level | < 1 EU/μg of protein by gel clotting method | |
| Biological Activity | ED50 < 10.0 ng/ml, measured by the dose-dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 U/mg. | |
| Expression System | E. coli | |
| Apparent Molecular Weight | ~9.1 KDa, on SDS-PAGE under reducing conditions. | |
| Formulation | Lyophilized after extensive dialysis against 50 mM acetic acid. | |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 10 mM HCl up to 1mg/ml. | |
| Storage & Stability | Upon receiving, this product remains stable for 6 months at lower than -70°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
»
»
ED50 < 10.0 ng/ml, measured by the dose dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg. »
Lane 1: 2 μg of LR3-IGF-I (Receptor Grade), Human, non-reducing (NR)
Lane 2: 2 μg of LR3-IGF-I (Receptor Grade), Human, reducing (R)
> 95% as analyzed by SDS-PAGE
»
| Target Background | IGF-1 is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-1 is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-1 (rhLR3IGF-1) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3)and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs. |
| Synonyms | LR3 Insulin-like Growth Factor-I; LR3-IGF-I |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.